Literature DB >> 33714262

Safety and feasibility of total laparoscopic radical resection of Siewert type II gastroesophageal junction adenocarcinoma through the left diaphragm and left thoracic auxiliary hole.

Yun Huang1, Gang Liu1, Xiumei Wang1, Yan Zhang1, Guijun Zou1, Zhanwei Zhao1, Zhen Cao1, Huibin Zhao1, Xinpu Yuan1, Chaojun Zhang2.   

Abstract

BACKGROUND: The incidence of adenocarcinoma of the esophagogastric junction (AEG) is rising every year; however, the mode of operation for Siewert II AEG is still controversial. Accumulating evidence has shown that transabdominal surgery is better than transthoracic surgery for Siewert II AEG with esophageal invasion < 3 cm. In patients with obesity, a large tumor size, and high transection of the esophagus, the transabdominal esophageal hiatus approach for lower mediastinal lymph node dissection and posterior mediastinal anastomosis is difficult. Thus, total laparoscopic radical resection of Siewert II AEG is carried out through the left diaphragm and left chest auxiliary hole for the optimal surgical field of vision and space. In this prospective study, we assessed the feasibility of carrying out the procedure abdominally through the left diaphragm and auxiliary hole.
METHODS: Ten patients with Siewert II AEG were recruited between April and June 2019. Siewert II AEG was treated by total laparoscopy through the left diaphragm and left chest auxiliary hole. Clinicopathological features, surgical data, and adverse events were collected and analyzed in this prospective study.
RESULTS: The average duration of the operation was 348 ± 37.52 min, lower mediastinal dissection took 20.6 min, the OrVil anastomosis time was 29.8 min, the time necessary to suture the seromuscular layer through the left thoracic auxiliary hole was 11 min, the safety margin was 3.2 cm, and the total number of lymph nodes dissected was 40.6. The number of lower mediastinal lymph nodes dissected was 6.2. The rate of lymph node metastasis in the N110 group was 9 ± 12.45%, and the average intraoperative blood loss was 170 ± 57.47 mL. No anastomotic leakage or anastomotic stricture occurred after the operation. The time of intestinal function recovery was 2 days, and the first time of enteral nutrition through a jejunal nutrition tube was 2.4 days. No tumor recurrence was found in 10 patients at 1 year postoperatively.
CONCLUSION: Total laparoscopic radical resection through the left diaphragm and left thoracic auxiliary hole for Siewert II AEG patients is feasible and safe. Thus, it may be a good surgical alternative for patients with esophageal tumors invading less than 3 cm. TRIAL REGISTRATION: ChiCTR, ChiCTR2000034286. Registered 8 July 2020, http://www.chictr.org.cn/showproj.aspx?proj=55866 .

Entities:  

Keywords:  Adenocarcinoma of the esophagogastric junction; Laparoscopic surgery; Minimally invasive treatment; Siewert type II

Mesh:

Year:  2021        PMID: 33714262      PMCID: PMC7956135          DOI: 10.1186/s12957-021-02183-9

Source DB:  PubMed          Journal:  World J Surg Oncol        ISSN: 1477-7819            Impact factor:   2.754


  15 in total

1.  Laparoscopic mediastinal dissection via an open left diaphragm approach for advanced Siewert type II adenocarcinoma.

Authors:  Shuji Takiguchi; Yasuhiro Miyazaki; Naoki Shinno; Tomoki Makino; Tsuyoshi Takahashi; Yukinori Kurokawa; Makoto Yamasaki; Kiyokazu Nakajima; Hiroshi Miyata; Masaki Mori; Yuichiro Doki
Journal:  Surg Today       Date:  2015-09-15       Impact factor: 2.549

2.  Clinicopathological features and prognostic factors of adenocarcinoma of the esophagogastric junction according to Siewert classification: experiences at a single institution in Japan.

Authors:  Yuichi Hosokawa; Takahiro Kinoshita; Masaru Konishi; Shinichiro Takahashi; Naoto Gotohda; Yuichiro Kato; Hiroyuki Daiko; Mitsuyo Nishimura; Kenji Katsumata; Yasuyuki Sugiyama; Taira Kinoshita
Journal:  Ann Surg Oncol       Date:  2011-08-06       Impact factor: 5.344

3.  Short-term outcomes after laparoscopic versus open transhiatal resection of Siewert type II adenocarcinoma of the esophagogastric junction.

Authors:  Shizuki Sugita; Takahiro Kinoshita; Akio Kaito; Masahiro Watanabe; Hideki Sunagawa
Journal:  Surg Endosc       Date:  2017-06-27       Impact factor: 4.584

4.  A prospective randomized controlled trial of semi-mechanical versus hand-sewn or circular stapled esophagogastrostomy for prevention of anastomotic stricture.

Authors:  Wen-Ping Wang; Qiang Gao; Kang-Ning Wang; Hui Shi; Long-Qi Chen
Journal:  World J Surg       Date:  2013-05       Impact factor: 3.352

5.  Risk factor analysis for involvement of resection margins in gastric and esophagogastric junction cancer: an Italian multicenter study.

Authors:  Massimiliano Bissolati; Matteo Desio; Fausto Rosa; Stefano Rausei; Daniele Marrelli; Gian Luca Baiocchi; Giovanni De Manzoni; Damiano Chiari; Giovanni Guarneri; Fabio Pacelli; Lorenzo De Franco; Sarah Molfino; Chiara Cipollari; Elena Orsenigo
Journal:  Gastric Cancer       Date:  2016-01-05       Impact factor: 7.370

6.  [Cardia cancer: attempt at a therapeutically relevant classification].

Authors:  J R Siewert; A H Hölscher; K Becker; W Gössner
Journal:  Chirurg       Date:  1987-01       Impact factor: 0.955

7.  Stenosis after esophagojejunostomy with the hemi-double-stapling technique using the transorally inserted anvil (OrVil™) in Roux-en-Y reconstruction with its efferent loop located on the patient's left side following laparoscopic total gastrectomy.

Authors:  Takaya Tokuhara; Eiji Nakata; Toshiyuki Tenjo; Isao Kawai; Keisaku Kondo; Hirofumi Ueda; Atsushi Tomioka
Journal:  Surg Endosc       Date:  2018-10-19       Impact factor: 4.584

8.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

9.  Lymphadenectomy around the left renal vein in Siewert type II adenocarcinoma of the oesophagogastric junction.

Authors:  S Mine; T Sano; N Hiki; K Yamada; S Nunobe; T Yamaguchi
Journal:  Br J Surg       Date:  2012-11-23       Impact factor: 6.939

10.  Ten-year follow-up results of a randomized clinical trial comparing left thoracoabdominal and abdominal transhiatal approaches to total gastrectomy for adenocarcinoma of the oesophagogastric junction or gastric cardia.

Authors:  Y Kurokawa; M Sasako; T Sano; T Yoshikawa; Y Iwasaki; A Nashimoto; S Ito; A Kurita; J Mizusawa; K Nakamura
Journal:  Br J Surg       Date:  2015-01-21       Impact factor: 6.939

View more
  4 in total

1.  Comparison of Efficacy Between Transabdominal and Transthoracic Surgical Approaches for Siewert Type II Adenocarcinoma of the Esophagogastric Junction: A Systematic Review and Meta-Analysis.

Authors:  Zonglin Li; Huaiwu Jiang; Jin Chen; Yifan Jiang; Yi Liu; Linxia Xu
Journal:  Front Oncol       Date:  2022-04-29       Impact factor: 5.738

2.  Advantages of McKeown minimally invasive oesophagectomy for the treatment of oesophageal cancer: propensity score matching analysis of 169 cases.

Authors:  Jun Xie; Lei Zhang; Zhen Liu; Chun-Lei Lu; Guang-Hui Xu; Man Guo; Xiao Lian; Jin-Qiang Liu; Hong-Wei Zhang; Shi-Ying Zheng
Journal:  World J Surg Oncol       Date:  2022-02-25       Impact factor: 2.754

3.  Total laparoscopic versus laparoscopic-assisted transabdominal posterior mediastinal digestive tract reconstruction in the treatment of Siewert II adenocarcinoma of the esophagogastric junction: A retrospective study.

Authors:  Liang Wang; Xiaoqian Chen; Wei Miao; Yubin Ma; Xinfu Ma; Chun Wang; Xiaobo Cao; Hongyin Xu; Jiajia Wei; Su Yan
Journal:  Front Surg       Date:  2022-08-19

4.  Whether the infracardiac bursa protect right pleura during laparoscopic radical operation of Siewert type II adenocarcinoma of esophagogastric junction?

Authors:  Zeyu Lin; Haiping Zeng; Wenjun Xiong; Jin Li; Yan Chen; Lijie Luo; Yansheng Zheng; Zhuoxuan Zhang; Wei Wang
Journal:  BMC Cancer       Date:  2022-08-27       Impact factor: 4.638

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.